Study At The Man Of The Profile Of Chimiokines In The Anorexia Bound To The Cancerous Cachexy

Study Overview

Study at the Man of the Profile of Chimiokines in the Anorexia Bound to the Cancerous Cachexy

The syndrome of anorexia-cachexie, which accompanies numerous cancers is a major comorbidity which compromises the forecast of these patients. Several cytokines pro-inflammatory as interleukines IL1 ß, IL6 or TNFa participate in the physiopathology of this syndrome at the man and the animal. Besides, it is now established that different neuronal populations, localized in the hypothalamus, are nerve centers of the control of the appetite and the energy homéostasie. However, there is not enough evidence of a direct action of cytokines on these neurones, suggesting the participation of intermediate molecules as chimiokines, inflammatory molecules produced in reaction to an immunological stress by gliales cells and acting directly on the surrounding neurones. The implication of chimiokines in the syndrome of anorexia-cachexie associated with the cancer thus seems very likely Among these, chimiokines " Monocyte Chemoattractant Proteins 1-3 " or MCPs represent obvious candidates because they are produced by multiple tumors. Furthermore, to the mouse, the intellectual expression of MCP1 is correlated in the anorexia led by peripheral injections of a bacterial by-product, the lipopolysaccharide (LPS). The investigators' main objective is to test at the Man's, in situation of cancer of the pancreas any confused stages, the degree of prédictivité of the chimiokine MCP1 towards the syndrome of anorexia-cachexie associated with the cancer. The investigator also suggest describing: i) the link between rate plasmatique of MCP1 and energy metabolism on one hand, physical composition on the other hand;; ii) the impact of the other chimiokines, particularly those of the family of the MCPs, on the anorexia-cachexie bound to the cancer, iii) the correlation enters their profile of expression plasmatique and the severity of the anorexia, the energy metabolism and the physical composition; iv) the same research on the other inflammatory factors plasmatiques, of nature different from chimiokines; v) the correlation between thin mass and anorexia; vi) the evolution of the chimiokines various and inflammatory factors after surgical treatment or chemotherapy with curative aim in 6 months.

N/A

Cancer of the Pancreas
Anorexia

OTHER: Dosage of chimiokines

12-PP-03

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates	Results Reporting Dates	Study Record Updates
First Submitted 2012-07-20	Results First Submitted N/A	Last Update Submitted that met QC Criteria 2022-10-24
First Submitted that Met QC Criteria 2016-07-08	Results First Submitted that Met QC Criteria N/A	Last Update Posted (ACTUAL) 2022-10-26
First Posted (ACTUAL) 2016-07-13	Results First Posted N/A	Last Verified 2022-10

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Basic Science

Allocation:
Non Randomized

Interventional Model:
Parallel

Masking:
None

Arms and Interventions

Participant Group/Arm	Intervention/Treatment
OTHER: groupe1 cancer of the pancreas WITH syndrome of anorexia-cachexie Dosage of chimiokines	OTHER: Dosage of chimiokines
OTHER: groupe2 cancer of the pancreas WITHOUT syndrome of anorexia-cachexie Dosage of chimiokines	OTHER: Dosage of chimiokines
OTHER: groupe3 pure food limitation typifies restrictive anorexia nervosa Dosage of chimiokines	OTHER: Dosage of chimiokines
OTHER: groupe4 unhurt individual of any appetite-suppressing evolutionary disease and cachectisante Dosage of chimiokines	OTHER: Dosage of chimiokines

Primary Outcome Measures	Measure Description	Time Frame
chimiokine MCP1 expression	Study at the Man's, in situation of cancer of the pancreas, diagnosed of novo and any confused stages, the prediction of the chimiokine MCP1 towards the syndrome of anorexia-cachexie associated with the cancer	change from baseline to 180 days

Secondary Outcome Measures	Measure Description	Time Frame

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

Patient to hospitalize in the unit of digestive cancer research.
Patient ≥ 18 years.
Patient carrier of an adénocarcinome of the pancreas of novo, any stadium confused, diagnosed by imaging and/or histology.
Existence of at least one of the criteria following to hold(retain) the diagnosis of cachexie cancer patient: not deliberate loss of weight > in 5 % over the last 6 months OR(WHERE) IMC(CEREBRAL-MOTOR HANDICAPPED) < 20 kg / m ² with a loss of minimum weight > 2 % OR(WHERE) scrawny muscular index appendiculaire respectively < 7,26 kg / m ² at the man and < 5,45 kg / m ² at the woman with a minimal weight loss > 2 %.
Patient having signed the enlightened consent.

Patient having a tumor other one than the pancreatic adénocarcinome.
Patient having a second offense of adénocarcinome pancreatic.
Patient carrier of a pancreatic adénocarcinome in the course of a treatment by chemotherapy.
Patient having a severe psychiatric comorbidity except TCA who can be responsible for food disorders.
Patient carrier of an evolutionary inflammatory disease other one than the cancer being able to interfere on the inflammatory status.

Patient to hospitalize in the(unit) of digestive cancer research.
Patient ≥ 18 years.
Patient carrier of an adénocarcinome of the pancreas of novo, any stadium confused, diagnosed by imaging and/or histology.
Patient having signed a enlightened consent.

Patient having a tumor other one than the pancreatic adénocarcinome.
Patient having a second offense(recurrence) of adénocarcinome pancreatic.
Patient carrier of a pancreatic adénocarcinome in the course of a treatment by chemotherapy.
Existence of at least one of the criteria in favour of the diagnosis of cachexie cancer patient: not deliberate loss of weight > in 5 % over the last 6 months OR(WHERE) IMC(CEREBRAL-MOTOR HANDICAPPED) < 20 kg / m ² with a loss of minimum weight > 2 % OR(WHERE) scrawny muscular index appendiculaire respectively < 7,26 kg / m ² at the man and < 5,45 kg / m ² at the woman with a minimal weight loss > 2 %.
Patient having a severe psychiatric comorbidity except TCA who can be responsible for food disorders.
Patient carrier of an evolutionary inflammatory disease other one than the cancer being able to interfere on the inflammatory status.
Patient refusing to participate in the study
Under guardianship patient or guardianship.

Patient seen in consultation in the unit of nutritional support(medium)
Patient ≥ 18 years.
Patient carrier of an eating disorder of type pure restrictive anorexia nervosa (according to criterion diagnosis of the WHO)
Patient having signed a enlightened consent.

Patient having any evolutionary organic pathology source of a decrease of the oral contributions and/or the interference on the inflammatory status, and responsible for a loss of weight
Patient refusing to participate in the study
Under guardianship patient or guardianship.

Patient seen in consultation of hepatogastroenterology
Patient ≥ 18 years.
Unhurt patient of any organic or psychic, evolutionary pathology, cachectisante
Patient having signed a enlightened consent.

Patient refusing to participate in the study
Under guardianship patient or guardianship.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

PRINCIPAL_INVESTIGATOR: Stéphane SCHNEIDER, Pr, Centre Hospitalier Universitaire de Nice

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available

Learn

Resources

Patients

Caregivers

Clinical Trial Record